Pediatric Oncology, National Cancer Institute (NCI), Cairo University and Children Cancer Hospital of Egypt (CCHE), Cairo, Egypt.
Department of Radiation Oncology, National Cancer Institute, Cairo University and Children Cancer Hospital (CCHE), Cairo, Egypt.
J Egypt Natl Canc Inst. 2021 Sep 20;33(1):26. doi: 10.1186/s43046-021-00083-3.
The survival of pineoblastoma patients is low, particularly in infants and those with metastatic disease. This study aimed to analyze the prognostic factors affecting the outcome of Pineoblastoma in different age groups.
A retrospective study included 33 patients. Twenty-two patients older than 3 years had upfront surgery, followed by induction CSI then 6 cycles of chemotherapy. Eleven patients younger than 3 years underwent surgery, followed by induction chemotherapy then radiation therapy. Focal irradiation (54 Gy) was administrated in six patients, and CSI (23.4 Gy) with booster dose 30.6 Gy to the tumor bed in two patients followed by 4 cycles of chemotherapy.
Patient's age showed a significant impact on the outcome (P value = 0.001 for EFS and 0.002 for OS). The metastases' presence did not impact the outcome negatively. The survival of patients with metastatic disease did not differ between age groups. However, age had a significant impact on the outcome of M0 disease, with 3-year EFS and OS of 65.3% and 74%, respectively, in the older group compared to 0% for both rates in younger patients. CSI showed a positive impact on survival. For all cases, the 3-year OS and EFS were 46.7% and 44.4%, respectively.
A multimodality approach is needed to treat this aggressive disease. Inadequate dose intensity affected our patients' outcome negatively. A more aggressive approach using high-dose chemotherapy or CSI may be required to improve infantile pineoblastoma's dismal outcome. Focal radiotherapy is not an efficacious treatment in infants due to its high-metastatic potential. Molecular typing should be considered to label patients who need a more intensified approach.
成松果体细胞瘤患者的生存率较低,尤其是婴儿和转移性疾病患者。本研究旨在分析影响不同年龄段成松果体细胞瘤预后的因素。
回顾性研究纳入 33 例患者。22 例年龄大于 3 岁的患者行 upfront 手术,随后行诱导性 CSI 及 6 个周期化疗。11 例年龄小于 3 岁的患者行手术,随后行诱导化疗及放疗。6 例患者行局部照射(54Gy),2 例患者行 CSI(23.4Gy)加肿瘤床 Booster 剂量 30.6Gy,随后行 4 个周期化疗。
患者年龄对预后有显著影响(EFS 的 P 值=0.001,OS 的 P 值=0.002)。转移的存在并不对预后产生负面影响。转移性疾病患者的生存情况在不同年龄组之间没有差异。然而,年龄对 M0 疾病的预后有显著影响,年龄较大组的 3 年 EFS 和 OS 分别为 65.3%和 74%,而年龄较小组的这两个比率均为 0%。CSI 对生存有积极影响。所有病例的 3 年 OS 和 EFS 分别为 46.7%和 44.4%。
需要采用多模式方法来治疗这种侵袭性疾病。剂量强度不足对我们患者的预后产生负面影响。为了改善婴儿成松果体细胞瘤的不良预后,可能需要采用更积极的高剂量化疗或 CSI 方法。由于其高转移潜能,局部放疗对婴儿无效。应考虑分子分型,以确定需要更强化治疗的患者。